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A Protein-Free Process and 
Product Protection System
Stephen Ward


























How do Excipients work
1. Charge screening – screen ionic 
interactions 
2. Hydration – preferentially excluded 
increasing hydration of molecule







3.   Chaperone molecules - bind to the 
active molecule inhibiting aggregation
3.   Prevent denaturation – inhibit 






interaction with ice 
crystals













Excipients substitute for water 










Excipients form a viscous amorphous
region around molecule preventing 














 Novel excipients are screened 
for efficacy in formulations
Optimisation: 
 Successful candidates are 
further characterised and 
their formulation optimised.
Long-Term:
 Optimal formulations are 
tested in confirmational 
studies which define the 










Live Adenovirus  
Live Measles virus (Schwartz)
Live Foot-and-Mouth Disease
Inactivated Influenza (PR8)
Live Canine viruses 
Live Modified Vaccinia Ankara
Therapeutic Antibodies
Therapeutic Fab’s















ST ILITE  
TE L
To prevent against the various degradation 
mechanisms stabilization mixes are formed from a 
panel of excipients
The base of the formulation is comprised of GRAS 
listed agents (sugar/sugar alcohol)
These are supplemented with small  chemical 
Stabilitech Excipients
reagents which have either:
Been used in clinical trials
Been used in human Nutraceutical products
To further underscore the non-toxic nature of 
these excipients full GLP toxicological studies have 
been carried out (including immunotox) with no 
measurable toxic effects 
Regulatory Support
Review existing non-clinical safety data 



































Compile Excipient Master File for customer use










































Review existing non-clinical safety data 


















Compile Excipient Master File for customer use
Perform targeted safety studies for key excipients 
alone




















•Pharmacopeal excipients already widely available
•Lesser-used excipients being made by blue chip CMO in UK 
•MHRA and FDA Licence 
•Second EU suppliers also identified
GMP Supply of Excipients





•Pharmacopeal excipients already widely available
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CMC Scale-up of Technology
Stabilitech in-house capacity
400 x 2 ml DIN vials
0.5ml fill volume
Scale-up with CRO
1800 x 3ml vials
1.5ml fill volume
Stability Achievements
 Protection against Production losses
 Superior to established viral formulations
 Allow Alum adjuvant to be frozen
 Protection against high and low temperature 
excursions
 Significant improvement over industry gold-standard 
virus formulation
 Enhanced long-term stability






Vector in novel vaccines
Gene therapy vehicle
Often an unstable product:
Evans et al. (2004)
Liquid 4°C  2 year
Croyle et al. (2001) 
Lyophilised 4°C 1 year
Stabilitech: liquid and Lyophilised
Adenovirus Protection against
Process Loss
*35% *12% *41% *93% *79%
GFP assay of 
formulations post 
lyophilisation.
<0.5 log loss success 
target
*Percentage  Loss during lyophilisation
Success criteria 
achieved with all 
formulations
Out perform Best 
published formulation
Liquid Protection of Adenovirus 
against Excursions: 40°C for 14 days
GFP assay of liquid 
formulations after 
40oC for 2 weeks





Only a <1 log loss in 
AB1 and AB5
WHO: VVM 14
Liquid Stability of Adenovirus:
up to 25°C for 6 Months
0.5 Log Loss*
*
GFP assay of liquid 
formulations after 
storage at 4oC  and 25oC 
for 6 months
 <0.5 log loss in Merck 
A195 Buffer at 4oC, and 
1.5 log loss at 25oC








well at 3 months so far
2 year study ongoing
Liquid Stability of Adenovirus:
up to 25°C for 9 Months
GFP assay of liquid 
formulations after 
storage at 4oC  and 25oC 
for 9 months







* Significant improvement to Merck A195 Buffer at 95% 
confidence interval 
protection  with AB9 and 
A31 compared to Merck 
A195
 Opimised sugar-
component  only A and 
AB  insufficient at 
ambient temperatures
2 year study ongoing
Lyophilised Stability of Adenovirus: 
up to 40°C for 6 Months
GFP assay of lyophilised 
formulations after storage 
at 4oC, 25oC and 40°C for 6 
months
<0.5 log loss success target
Less than half log loss of 
0.5 Log Loss
* * * *
* * *
Adenovirus at 4oC and 25oC
Recoverable virus even at 
40°C 
Less than two log 
loss of Adenovirus at 
40oC
* Significant difference to post lyophilised at 95% 
confidence interval 
Enveloped virus
Genus Morbillivirus in the family 
Paramyxoviridae.
Measles Virus
Widely regarded, after polio, as one of 
the most temperature sensitive 
vaccines
Continuing need for thermally stable 
vaccine for developing world











 Repeated cycling from -20ºC (20 hours) to +37ºC (4 hours).
 Excipients protect against severe temperature excursions
Loss of Alhydrogel™ structure:
 Lyophilisation not previously possible 
Accidental freezing during cold chain





Separate alum and antigen containers




Lyophilised Formulation B Lyophilised HEPES control
• Structural retention 90% • Structural retention 7%
Lyophilised: Protection of antigen 































































Labile antigen also protected along with Alhydrogel
Unformulated (Buffer)                            Formulated
• Particle size distribution of alum (0.26%) before and after freezing.
• Addition of formulation prevents agglomeration





























100ug/ml rPA - 0.26% 
Alhydrogel HEPES FT -
Averageii
100ug/ml rPA - 0.26% 
Alhydrogel 1M DMG 
FT - Average
100ug/ml rPA - 0.26% 
Alhydrogel DTMphos 
FT - Average
100ug/ml rPA - 0.26% 




Freeze Alum + 
formulation a
Freeze lum + 
formulation b
Freez Alum + 
formulation c













































































Liquid Stability of rPA adsorbed to





























Formulated                                           Unformulated
 Significant improvement in protection to antigen adsorbed to 





















Toxin Neutralising Antibody  Levels in Rabbits  
Vaccinated with rPA Adsorbed to Alhydrogel™ 






1:50 1:250 1:1250 1:6250 1:31250 1:156250 1:781250 +ve 1:50 + 
LT









1 way ANOVA 1:50 p=0.72 1:250 p=0.62
Safe and Compliant technology
Wide vaccine-type utility
Commonly used Alum adjuvant
Protects fragile material during processing 
Significant COG impact
Prevents future stability losses
Technology Conclusions
Excellent product protection
Prevents freeze and high temperature excursion losses
Widens distribution and administration options
Potential for cold-chain removal itself
Novel intellectual property position
In vivo toxicology showed no adverse reaction
Delighted to speak to you about potential 
feasibility studies to evaluate our 
Technology with your vaccine
stephen@stabilitech.com
www.stabilitech.com
